Table 1 Baseline demographic characteristics of the 72 patients with active ulcerative colitis (UC), sub-grouped as responders, partial-responders or non-responders following infliximab (IFX) induction therapy

Male, number (%)

13 (44.8)

14 (58.3)

12 (63.2)

0.4117

0.2500

Age, year

37.5 [30.3–54.4]

37.6 [32.3–45.5]

26.1 [20.2–36.4]

0.9929

0.0315

Duration of UC, year

5.4 [1.8–9.3]

6.3 [2.6–10.4]

2.5 [1.0–6.1]

0.5028

0.0958

Duration (days) of active UC prior to IFX induction

38.0 [26.5–63.0]

107.0 [30.5–178.8]

101.0 [41.0–153.0]

0.0255

0.0072

Dose of infused IFX (mg/kg)

6.2 [5.3–6.7]

5.7 [5.5–6.2]

6.1 [5.3–6.6]

0.4579

0.9411

CRP (mg/dL)

1.17 [0.41–2.74]

1.28 [0.32–2.11]

0.59 [0.26–1.16]

0.8302

0.1739

Albumin (g/dL)

4.4 [4.2–4.6]

4.1 [4.0–4.3]

4.0 [3.7–4.3]

0.0006

0.0022

Haemoglobin (g/dL)

12.3 [11.4–13.6]

12.8 [11.1–13.7]

11.9 [9.9–13.4]

0.9715

0.2820

Partial Mayo Score (0–9)

7 [5–7]

7 [6–8]

7 [5–7]

0.1020

0.8872

UC location, number (%)

Extensive

23 (79.3)

16 (66.7)

15 (79.0)

0.3579

1.0000

Left-sided

6 (20.7)

8 (33.3)

4 (21.1)

0.3579

1.0000

Corticosteroid dependent, number (%)

18 (62.1)

20 (83.3)

10 (52.6)

0.1274

0.5613

Corticosteroid refractory, number (%)

10 (34.5)

1 (4.2)

9 (47.4)

0.0075

0.5469

Concomitant medication, number (%)

5-Aminosalicylates

27 (93.1)

23 (95.8)

18 (94.7)

1.0000

1.0000

Corticosteroids

20 (69.0)

14 (58.3)

16 (84.2)

0.5662

0.3157

Azathioprine/ Mercaptopurine

8 (27.6)

6 (25.0)

6 (31.6)

1.0000

1.0000

Previously failed ≥2 immunosuppressant, number (%)

5 (17.2)

1 (4.2)

8 (46.2)

0.2044

0.0959

Smoking status, number (%)

Currents smoker

2 (6.9)

3 (12.5)

1 (5.3)

0.6486

1.0000

Nonsmoker

24 (82.8)

21 (87.5)

14 (73.7)

0.7153

0.4873

Past smoker

3 (10.3)

0 (0)

4 (21.1)

0.2424

0.4116